Veru Inc. (VERU)
Automate Your Wheel Strategy on VERU
With Tiblio's Option Bot, you can configure your own wheel strategy including VERU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VERU
- Rev/Share 0.0725
- Book/Share 0.1438
- PB 4.1939
- Debt/Equity 0.161
- CurrentRatio 3.8043
- ROIC -1.1032
- MktCap 88390152.0
- FreeCF/Share -0.1995
- PFCF -3.027
- PE -2.4286
- Debt/Assets 0.1037
- DivYield 0
- ROE -1.2362
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Anthea Li - Jefferies Gary Nachman - Raymond James William Wood - B. Riley Securities Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.
Read More
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
Read More
Veru Participates in a Virtual Investor KOL Connect Segment
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP.
Read More
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --
Read More
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update.
Read More
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Veru Inc (NASDAQ:VERU ) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications. Mitchell Steiner - Chairman, Chief Executive Officer and President Michelle Greco - CFO and CAO Gary Barnette - Chief Scientific Officer Conference Call Participants William Wood - B.
Read More
About Veru Inc. (VERU)
- IPO Date 1999-02-11
- Website https://www.verupharma.com
- Industry Biotechnology
- CEO Dr. Mitchell S. Steiner F.A.C.S., M.D.
- Employees 210